Nuformix PLC Issue of Equity (3019R)
28 Octubre 2019 - 2:30AM
UK Regulatory
TIDMNFX
RNS Number : 3019R
Nuformix PLC
28 October 2019
28 October 2019
Nuformix plc
("Nuformix" or "the Company"),
Issue of Equity
Following the receipt of Notice of Conversion of Loan Note,
8,716,512 ordinary shares of 0.1p each in the Company (the "Loan
Note Shares") have been issued to the Loan Note holder following
exercise at the agreed price of 2.75p per share.
Application has been made to admit the Loan Note Shares to
trading on the London Stock Exchange on 24 October 2019, and
dealings in the Loan Note Shares are expected to commence on 29
October 2019.
The Company's announcement on this matter on 24 May 2019 refers
to the issue of equity referred to above.
The Company further announces that following the receipt of
Notice of Exercise, 250,000 ordinary shares of 0.1p each in the
Company (the "Warrant Shares") have now been issued to the Warrants
holder following exercise at the agreed price of 4p per share.
Application has been made to admit the Warrant Shares to trading
on the London Stock Exchange on 24 October 2019, and dealings in
the Warrant Shares are expected to commence on 29 October 2019.
Following the issue of the Loan Note Shares and Warrant Shares
the total number of shares now in issue is 469,716,512 ordinary
shares with voting rights attached (one vote per share). There are
no shares held in treasury.
This total voting rights figure may be used by shareholders as
the denominator for the calculations by which they will determine
whether they are required to notify their interests in, or a change
to their interest in, Nuformix plc under the Disclosure and
Transparency Rules.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 62722
Email: info@nuformix.com
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix's IP portfolio of granted patents covers cocrystal
forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEGMMZGRRFGLZG
(END) Dow Jones Newswires
October 28, 2019 04:30 ET (08:30 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024